PMV PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Payable
PMV PHARMACEUTICALS, INC. (PMVP) reported Increase (Decrease) in Accounts Payable of -$1.14 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $389.00K.
- PMV PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$1.52M.
- PMV PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$244.00K, a 105.40% decline year-over-year.
- PMV PHARMACEUTICALS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $801.00K.
- PMV PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2025 was -$3.42M, a 202.45% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2024 was $3.34M, a 1322.13% increase from fiscal 2023.
- PMV PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2023 was $235.00K.
- PMV PHARMACEUTICALS, INC. increase (decrease) in accounts payable for fiscal 2022 was -$389.00K, a 303.66% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $389.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.14M 10-Q · filed 2026-08-14 | -$1.38M derived: sum of 3 quarters · filed 2026-08-14 | -$578.00K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$1.52M 10-Q · filed 2026-05-12 | -$1.77M derived: sum of 2 quarters · filed 2026-05-12 | -$967.00K derived: sum of 3 quarters · filed 2026-05-12 | -$1.96M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$244.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $557.00K derived: sum of 2 quarters · filed 2026-03-06 | -$438.00K derived: sum of 3 quarters · filed 2026-08-14 | -$3.42M 10-K · filed 2026-03-06 |
| 2025-09-30 | $801.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$194.00K derived: sum of 2 quarters · filed 2026-08-14 | -$3.18M 10-Q · filed 2025-11-12 | $1.34M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$995.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$3.98M 10-Q · filed 2026-08-14 | $535.00K derived: sum of 3 quarters · filed 2026-08-14 | -$1.94M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$2.99M 10-Q · filed 2026-05-12 | $1.53M derived: sum of 2 quarters · filed 2026-05-12 | -$940.00K derived: sum of 3 quarters · filed 2026-05-12 | $2.74M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $2.05M derived: sum of 2 quarters · filed 2026-03-06 | $5.73M derived: sum of 3 quarters · filed 2026-03-06 | $3.34M 10-K · filed 2026-03-06 |
| 2024-09-30 | -$2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.21M derived: sum of 2 quarters · filed 2025-11-12 | -$1.17M 10-Q · filed 2025-11-12 | $379.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-06-30 | $3.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.30M 10-Q · filed 2025-08-07 | $2.85M derived: sum of 3 quarters · filed 2026-03-06 | $1.04M derived: sum of 4 quarters · filed 2026-03-06 |
| 2024-03-31 | -$2.38M 10-Q · filed 2025-05-09 | -$831.00K derived: sum of 2 quarters · filed 2026-03-06 | -$2.64M derived: sum of 3 quarters · filed 2026-03-06 | -$629.00K derived: sum of 4 quarters · filed 2026-03-06 |
| 2023-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | -$258.00K derived: sum of 2 quarters · filed 2026-03-06 | $1.75M derived: sum of 3 quarters · filed 2026-03-06 | $235.00K 10-K · filed 2026-03-06 |
| 2023-09-30 | -$1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $202.00K derived: sum of 2 quarters · filed 2024-11-07 | -$1.32M 10-Q · filed 2024-11-07 | -$2.57M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $493.00K 10-Q · filed 2024-08-08 | -$763.00K derived: sum of 3 quarters · filed 2025-03-03 | $1.45M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$1.52M 10-Q · filed 2024-05-09 | -$2.78M derived: sum of 2 quarters · filed 2025-03-03 | -$567.00K derived: sum of 3 quarters · filed 2025-03-03 | -$2.15M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $953.00K derived: sum of 2 quarters · filed 2025-03-03 | -$628.00K derived: sum of 3 quarters · filed 2025-03-03 | -$389.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | $2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $628.00K derived: sum of 2 quarters · filed 2023-11-09 | $867.00K 10-Q · filed 2023-11-09 | $1.44M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$1.34M 10-Q · filed 2023-08-09 | -$766.00K derived: sum of 3 quarters · filed 2024-02-29 | -$1.91M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $239.00K 10-Q · filed 2023-05-10 | $815.00K derived: sum of 2 quarters · filed 2024-02-29 | -$332.00K derived: sum of 3 quarters · filed 2024-02-29 | $785.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $576.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$571.00K derived: sum of 2 quarters · filed 2024-02-29 | $546.00K derived: sum of 3 quarters · filed 2024-02-29 | $191.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | -$1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$30.00K derived: sum of 2 quarters · filed 2022-11-08 | -$385.00K 10-Q · filed 2022-11-08 | $1.21M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $762.00K 10-Q · filed 2022-08-09 | $2.36M derived: sum of 3 quarters · filed 2023-03-01 | $737.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | -$355.00K 10-Q · filed 2022-05-10 | $1.24M derived: sum of 2 quarters · filed 2023-03-01 | -$380.00K derived: sum of 3 quarters · filed 2023-03-01 | -$330.00K derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$25.00K derived: sum of 2 quarters · filed 2023-03-01 | $25.00K derived: sum of 3 quarters · filed 2023-03-01 | -$1.23M 10-K · filed 2023-03-01 |
| 2020-09-30 | -$1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$1.57M derived: sum of 2 quarters · filed 2021-11-12 | -$2.83M 10-Q · filed 2021-11-12 | -$742.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | -$1.21M 10-Q · filed 2021-08-13 | $878.00K derived: sum of 3 quarters · filed 2022-03-01 | |
| 2020-03-31 | -$1.25M 10-Q · filed 2021-05-14 | $828.00K derived: sum of 2 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $1.80M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | -$284.00K 10-Q · filed 2020-11-13 | |||
| 2018-12-31 | $267.00K 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |